1. Ultraviolet A (320–400 nm) Modulation of Ultraviolet B (290–320 nm)-Induced Immune Suppression Is Mediated by Carbon Monoxide 
Munif Allanson, Vivienne E. Reeve 
Journal of Investigative Dermatology 
Volume 124, Issue 3, Pages (March 2005)
DOI: /j X x
Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions

2. Figure 1
Time release of CO from the CO-RM. Slow decrease of absorbance over time by carbon monoxide-releasing molecule (CO-RM) in dimethyl sulfoxide, indicative of slow release of CO from the solution.
Journal of Investigative Dermatology  , DOI: ( /j X x)
Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions

3. Figure 2
Effect of fresh and aged CO-RM lotions on CHS. Contact hypersensitivity response to oxazolone in groups of five mice treated with increasing concentrations of fresh carbon monoxide-releasing molecule (CO-RM) (no significant differences) and aged CO-RM lotions, which became slightly immunosuppressive at 500 μM.
Journal of Investigative Dermatology  , DOI: ( /j X x)
Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions

4. Figure 3
Effect of CO-RM lotion on SSUVR-supressed CHS in the presence of the endogenous HO inhibitor SnPP. Contact hypersensitivity response to oxazolone in groups of five mice immunosuppressed by solar-simulated ultraviolet radiation (SSUVR) exposure, showing the partial protective effect of 500 μM carbon monoxide-releasing molecule (CO-RM) lotion, but not of 500 μM aged CO-RM lotion. Inhibition of endogenous heme oxygenase activity by injection of Sn protoporphyrin-IX (SnPP) slightly exacerbated SSUVR immunosuppression, but did not alter the CO-RM protection.
Journal of Investigative Dermatology  , DOI: ( /j X x)
Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions

5. Figure 4
Effect of CO-RM lotion on cis-UCA supressed CHS in the presence of the endogenous HO inhibitor SnPP. Contact hypersensitivity response to oxazolone in groups of five mice immunosuppressed by topical cis-urocanic acid (cis-UCA), showing the complete protective effect of 500 μM carbon monoxide-releasing molecule (CO-RM) lotion, but not of 500 μM aged CO-RM lotion. Inhibition of endogenous heme oxygenase activity by injection of Sn protoporphyrin-IX did not alter either cis-UCA immunosuppression, or the CO-RM protection.
Journal of Investigative Dermatology  , DOI: ( /j X x)
Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions

6. Figure 5
CO-RM concentration dependence for immunoprotection against cis-UCA. Contact hypersensitivity response to oxazolone in groups of five mice immunosuppressed by topical cis-urocanic acid, and the concentration-dependent protective effect of increasing carbon monoxide-releasing molecule lotion concentration.
Journal of Investigative Dermatology  , DOI: ( /j X x)
Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions

7. Figure 6
Effect of quanylyl cyclase inhibitor ODQ on UVA photoimmunoprotection. Contact hypersensitivity response to oxazolone in groups of five mice immunosuppressed by solar-simulated ultraviolet radiation exposure, showing the protective effect of ultraviolet A (320–400 nm) (UVA) irradiation, and the inhibition of the UVA protection by the guanylyl cyclase inhibitor 1H-(1,2,4)oxadiazolo-(4,3-1)quinoxaline-1-one.
Journal of Investigative Dermatology  , DOI: ( /j X x)
Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions

8. Figure 7
Effect of p38 MAPK inhibitor SB on UVA photo immunoprotection. Contact hypersensitivity response to oxazolone in groups of five mice immunosuppressed by solar-simulated ultraviolet radiation exposure, showing the protective effect of ultraviolet A (320–400 nm) irradiation, and the failure to alter this protection by the p38 mitogen-activated protein kinase inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl-5-4-(4-pyridyl) 1H-imidazole.
Journal of Investigative Dermatology  , DOI: ( /j X x)
Copyright © 2005 The Society for Investigative Dermatology, Inc Terms and Conditions